Kornimate/medical-research-clean huggingface dataset:
a morphological study in volleyball athletes with cronic ankle instability

Conditions: Ankle Injuries; Instability; Ankle (Ligaments) (Old Injury); Radiological Devices Associated With Adverse Incidents, Diagnostic and Monitoring Devices; Athlete Foot

Summary: the former purpose of this study to investigate the effect of transverse abdominis, lumbar multifidus, vastus lateralis, lateral gastrocnemius, anterior talofibular ligament of morphology on explosive power and balance performance in cronic ankle instability with volleyball players. the latter purpose of this study to determine morphological characteristics volleyball players with and without cronic ankle insatbility of trunk muscle morphology, field tests and the muscle morphology features between the body affected and unaffected sides whose those with chronic ankle instability.this study was designed as a cross-sectional. twelve volleyball players with chronic ankle instability who meet the criteria determined by the ankle consortium will be included in study group. twelve asymptomatic volleyball players who have been training at least three days a week for at least one year will be include in the control group. they will consist of 24 volleyball players between 14-35 years of age.morphological characteristics of anterior talofibular ligament, transverse abdominis, lumbar multifidus, vastus lateralis, lateral gastrocnemius will be evaluated via ultrasound, explosive power with squat jump, counter movement jump and balance performance by y-balance test. trunk muscle morphology, core stabilization, explosive power, balance performance will have been compered in volleyball players with and without chronic ankle instability. the effects of morphological features on explosive power and balance performance will have been determined. it is anticipated that by determining the parameters that can be affected by instability with volleyball players, it will guide the professionals working in the field, countribute to treatment and preventive treatment programs.


Eligibility criteria:
inclusion criteria: inclusion for the cai group followed the international ankle consortium guidelines. criteria for inclusion in the control group: to train for 1 hour at least 3 days a week for at least 1 year, cumberland ankle instability instrument (cait) score of 25 or higher, to have a tegner activity level of 4 and above, it is not to have a systemic disease exclusion criteria: the patient will be excluded from the study in the event of the presence of at least one of the following criteria: having undergone ankle, knee, hip surgery, having bilateral ankle instability, having suffered a known musculoskeletal injury of the hip having suffered an ankle sprain during the evaluation process criteria for exclusion from the study: withdraw to any period
peripheral nerve blocks in elderly patients with hip fracture

Conditions: Hip Fracture

Summary: as the population ages, the frequency of surgery is increasing proportionally, bringing with it the challenge of managing older patients with frequent comorbid diseases and an increased risk of complications. poor postoperative quality of recovery may result in patient and family suffering, a prolonged hospital stay, and a greater demand on health care resources.the purpose of this study was to evaluate the ultrasound guided percutaneous femoral nerve+lateral cutaneous nerve versus lumbar plexus+sacral plexus nerve block composite laryngeal mask anesthesia in elderly hip fracture surgery, the application of assessing their impact on the postoperative recovery quality.

in this study, patients who were more than 65 years old with hip fracture were randomized to peripheral nerve blocks 1(pnbs1)- femoral nerve+lateral cutaneous nerve-with laryngeal mask anesthesia, or peripheral nerve blocks 2(pnbs2) - lumbar plexus and sciatic - with laryngeal mask anesthesia. blocks were performed using ultrasound and 0.5% ropivacaine. all patients received postoperative multimodal analgesia. postoperative recovery was assessed at 15 minutes, 40 minutes,- 1 day, 3 days, and 7 days after surgery, with the postoperative quality of recovery scale, in physiological, nociceptive, emotive, modified activities of daily living, modified cognitive, and overall patient perspective domains.

Eligibility criteria:
inclusion criteria: 1. asa grade i \~ iii level; 2. the bmi \<30; 3. the mini - getting the state examination mmse \> 23; 4. the operation type:open reduction and internal fixation or bipolar head replace. exclusion criteria: 1. serious systemic diseases such as respiratory dysfunction, cardiac insufficiency, and renal insufficiency; 2. has a history of cognitive function disorder or mental illness; 3. has a history of cerebral infarction and leave sequela; 4. the blood coagulation dysfunction; 5. the hearing or visual impairment; 6. unable to complete assessment; 7. operation time more than 90 minutes; 8. the bleeding is greater than 1000 ml.

Keywords: nerve block general anesthesia hip fracture recovery
ddi study with multiple-dose lx4211 and single dose rosuvastatin

Conditions: Healthy

Summary: this study will be conducted as a single-center, open-label, 2-period, single-sequence, drug-drug interaction study to assess the effects of multiple-dose lx4211 400 mg (2 × 200-mg tablets qd × 7 days) on the pk of single-dose rosuvastatin (1 × 10-mg tablet) in healthy male and female subjects.


Eligibility criteria:
inclusion criteria: * adult subjects ≥18 to ≤55 years of age * vital signs at screening in the following ranges: systolic blood pressure, 90-140 mmhg; diastolic blood pressure, 50-90 mmhg; heart rate, 45-100 bpm * body mass index (bmi) ≥18 and ≤32 kg/sq m * willing and able to provide written informed consent exclusion criteria: * presence of clinically significant physical, laboratory, or ecg findings that, in the opinion of the investigator and/or sponsor, may interfere with any aspect of study conduct or interpretation of results * use of any medications or supplements/supratherapeutic doses of vitamins within 14 days prior to the first dose administration and throughout the duration of the study * receipt of any investigational agent or study drug within 30 days prior to screening * receipt of any protein- or antibody-based therapeutic agents within 3 months prior to screening * prior exposure to lx4211 * use of tobacco, smoking cessation products, or products containing nicotine within 3 months prior to screening and for the duration of the study * history of any serious adverse reaction or hypersensitivity to any inactive component of lx4211 or rosuvastatin * existence of any surgical or medical condition that might interfere with the absorption, distribution, metabolism, or excretion of lx4211 or rosuvastatin * history of any major surgery within 6 months or anticipated surgery prior to day * history of any clinically significant hypoglycemia or hyperglycemia * history of renal disease, or significantly abnormal kidney function test at screening * history of hepatic disease, or significantly abnormal liver function tests at screening * history of any clinically relevant psychiatric, renal, hepatic, pancreatic, endocrine, cardiovascular, neurological, hematological, or gi abnormality * history of any active infection within 14 days prior to day 1 * history of alcohol or substance abuse within 2 years prior to screening * positive hepatitis panel * donation or loss of \>500 ml of blood or blood product within 3 months prior to screening * women who are breastfeeding or are planning to become pregnant during the study, or women who have a positive serum pregnancy test * positive urine glucose at screening * positive urine screen for drugs of abuse and cotinine at screening, day -1, or day 13 * inability or difficulty swallowing whole tablets * unable or unwilling to cooperate with the investigator for any reason
the study of vidicizumab combined with tirelizumab in the treatment of breast cancer with low her2 expression

Conditions: Breast Cancer; Neoadjuvant Therapy

Summary: to evaluate the efficacy and safety of vidicizumab combined with tirelizumab in the treatment of early high-risk or locally advanced breast cancer with low her2 expression

studies have shown that vidicizumab has good efficacy and safety in advanced her-2 low expression breast cancer. vidicizumab combined with immunotherapy may be a new adjuvant treatment option for her-2 low expression breast cancer patients. therefore, we plan to carry out a clinical study to evaluate the efficacy, safety and tolerance of vidicizumab combined with tirelizumab during neoadjuvant therapy, in order to provide new treatment options for patients with breast cancer with her-2 low expression in neoadjuvant therapy, improve their prognosis and improve their quality of life

Eligibility criteria:
inclusion criteria: 1. age: 18 to 75 years old, male or female; 2. early or locally advanced breast cancer confirmed by pathology; 3. lymph node positive or lymph node negative, er and pr negative, t ≥ 2 or lymph node negative, er positive or pr positive, t ≥ 5; 4. ecog ps: 0-1; 5）patients with low expression of her-2: her-2 ihc 1+or her2 ihc 2+and ish negative; exclusion criteria: 1. stage iv breast cancer; 2. have received anti-tumor treatment or radiotherapy for any malignant tumor in the past five years, excluding cured cervical carcinoma in situ, skin basal cell carcinoma or squamous cell carcinoma; 3. at the same time, other clinical trials have received anti-tumor therapy. if the researcher judges that the patient cannot benefit from the researcher, other anti-tumor therapy can be ended. 4. the patient has undergone major surgery unrelated to breast cancer within 4 weeks before enrollment, or has not fully recovered from such surgery; 5. previously received adc drugs, immunosuppressants, anti-her2 and other treatments.
neptune pad ® compared to conventional manual compression

Conditions: Postoperative Hemorrhage

Summary: background. arterial access site complications remain the most frequent adverse events after percutaneous transluminal procedures. we investigated the safety and efficacy of the pro-coagulant wound dressing neptune pad ® compared to conventional manual compression for access site management after peripheral percutaneous interventions. methods. we enrolled 201 consecutive patients and randomly assigned patients for neptune pad ® (n=100) vs. conventional manual compression (n=101). patients were followed clinically until hospital discharge and by duplex ultrasound at 24 hours postprocedure for occurrence of access site complications. time-to-hemostasis and time-to-ambulation were recorded, patients´ and physicians´ discomfort were measured using a visual analogue scale.


Eligibility criteria:
inclusion criteria: * all inguinal punctures (common femoral, superficial femoral and deep femoral artery, antegrade and retrograde access) were included. * no specific limitations of anti-platelet or anti-coagulant medication were specified. exclusion criteria: * patients with extreme obesity (bmi above 35 kg/m2) were not included according to the manufactures' recommendations. * furthermore, patients with known hypersensitivity to components of the device were not eligible

Keywords: vascular access site arterial puncture femoral pseudoaneurysm
prognostic value of lung ultrasound in st segment elevation acute myocardial infarction (lus-ami)

Conditions: Acute Myocardial Infarction; Heart Failure

Summary: the purpose of this study is to asses the prognostic value of lung ultrasound in patients with st-segment elevation acute myocardial infarction.

lus-ami is an observational cohort prospective study that evaluates the prognostic value of lung ultrasound, specifically the number of b-lines, performed within the first 24 hours after and st-segment elevation acute myocardial infarction, by an independent operator blinded to clinical outcomes and off-line analysis by another independent operator also blinded to clinical outcomes. the primary outcome during hospitalization was a composite of clinically significant acute hf, cardiogenic shock, or death from any cause after lus was performed. new-onset atrial fibrillation, acute renal injury (acute kidney injury network ≥ 1), and need for ventilatory support (invasive or non-invasive) during hospitalization were also analyzed as secondary outcomes. the primary outcome during follow-up is one year after stemi is a composite of any cause mortality, hospitalization secondary to cardiovascular disease (aborted sudden cardiac arrest, acute coronary syndrome, heart failure or stroke) or need for urgent coronary revascularization. secondary outcomes are new onset heart failure during hospitalization, acute kidney injury during hospitalization, new-onset atrial fibrillation/flutter during hospitalization, need of ventilatory support during hospitalization and new-onset clinically relevant arrhythmia (atrial fibrillation, atrial flutter, ventricular tachycardia, ventricular fibrillation) during follow-up. a short-term follow-uo (30 days after prior pci) will be also performed to analyze a combined endpoint of death from any cause or hospitalization due to acute hf or new acute coronary syndrome.

Eligibility criteria:
inclusion criteria: * adults (more than 18 years) admitted with confirmed st-segment elevation acute myocardial infarction (stemi). exclusion criteria: * absence of coronary artery disease and myocardial injury (false positive) * non interpretable lung ultrasound * severe lung disease (fibrosis, severe copd, pleural disease, lobectomy or pneumonectomy) * acute respiratory distress syndrome * pneumonia or sdra at admission or during hospitalization * follow-up inability * hemodialysis therapy previous to admission * life expectancy less than 6 months secondary to extracardiac pathology.

Keywords: lung ultrasound
the effect of (l-prf) membrane in the treatment of gingival recession

Conditions: Localized Gingival Recession

Summary: evaluation of the use of l-prf membrane with coronally repositioned flap in treatment of localized gingival recession (class i \& ii) in comparison with the use of connective tissue graft

twenty patients, who are candidates for gingival recession coverage, will participate in this prospective clinical trial. group 1(10 patients) : coronally repositioned flap will be done and l prf membrane will be placed into the tissues group 2 (control group)(10 patients) : coronally repositioned flap will be done with sub epithelial connective tissue parameters * clinical evaluation of percentage of root coverage and keratinized tissue width * esthetic outcome evaluation will be done using the root coverage esthetic score (cairo et al. 2009) that include both evaluations will be done at 3, 6 and 9 months

Eligibility criteria:
inclusion criteria: * systemically free patients (american society of anesthesiologists i; asa i). * age range (20 -40) years. * good compliance with the plaque control instructions following initial therapy. * patients diagnosed with miller class i or ii in anterior and premolar teeth * availability for follow up and maintenance program. exclusion criteria: * patient suffering from periodontitis * presence of smoking habit. * presence of occlusion interference. * pregnant and lactating females. * vulnerable group of patients (handicapped, mentally retarded and prisoners).
awareness of individuals with chronic lung disease about climate change, heat waves, air pollution and physical activity

Conditions: Climate Change; Chronic Lung Disease; Air Pollution

Summary: climate change is characterized by global temperature increase, melting of glaciers and increasing temperature of ocean waters. increase in greenhouse gases such as nitrogen and carbon dioxide negatively affects air and water quality. extreme events such as extreme heat waves, floods and hurricanes are events seen with climate change. it is known that climate change and air pollution have negative effects on public health. its adverse effects are often seen in individuals with rhinosinusitis, asthma and chronic obstructive pulmonary disease. air pollution is expected to increase due to the ongoing economic growth and population growth worldwide, resulting in more respiratory diseases and disease burden. this study aims to assess the awareness level of individuals with chronic lung disease on climate change, heat waves, air pollution and their interaction with physical activity and anxiety and depression levels, and to better understand the experiences of patients and learn their perspectives. within the scope of the study, it is planned to provide patients brief information on this subject and receive feedback about this information.


Eligibility criteria:
inclusion criteria for the study: * being 18 years of age or older, * having a chronic lung disease (copd, asthma, bronchiectasis, cystic fibrosis, interstitial lung disease) and being referred to the cardiopulmonary rehabilitation unit of hacettepe university, faculty of physical therapy and rehabilitation for cardiopulmonary physiotherapy and rehabilitation, * being clinically stable, * using a smartphone with a pedometer, * to cooperate with the tests to be conducted, * being willing to participate in the study. exclusion criteria: * having had an acute exacerbation or having changed medication in the last month, * having a severe cardiovascular, orthopedic or neurological problem that may affect the tests.
eus-guided rfa for solid abdominal neoplasms

Conditions: Digestive System Neoplasms

Summary: radiofrequency ablation has been used for treatment of solid neoplasms of the liver, lung, kidney and adrenal. recently, eus-guided rfa has become available and the device allows eus-guided treatment of solid abdominal neoplasms. the procedure has been shown to be feasible in the porcine pancreas and was used to treat small groups of patients that are not suitable for surgery suffering from pancreatic cancers. the aim of the current study is to perform a multi-center prospective study on eus-guided radiofrequency ablation (rfa) of solid abdominal neoplasms. the hypothesis is that eus-guided rfa is safe, feasible and effective for treating solid abdominal neoplasms.

rfa causes tissue destruction through the application of a high frequency alternating current, generating local temperatures above 60°c and leading to coagulative necrosis. the technique has been widely used in many solid organ tumours and has been shown to result in 5-year survival rates comparable to surgery. the technique is currently the standard therapy in hepatocellular carcinoma and colorectal pulmonary metastasis particular in patients that are not suitable for surgery. the current study would be a multi-center prospective study involving four high volume international institutions. consecutive patients suffering from solid neoplasms of the liver, stomach and adrenals would be recruited. eus-guided rfa would be performed using a 19-gauge rfa electrode and a viva rf generator (starmed, korea). the primary outcome would be the overall adverse events rate. secondary outcomes include mortality, technical success rate, completion ablation rate, 1 \& 3 year overall and disease-free survival.

Eligibility criteria:
inclusion criteria: * age 18 years-old or above * suffering from solid neoplasms of the stomach, liver, kidney or adrenals (\<5cm in largest diameter) that is indicated for treatment. * unsuitable for surgery, due to one (or more) of the following items: * asa score \> ii\* * an alternative advanced malignancy * unsuitable for surgery upon expert's opinion for any other reason * healthy individuals who are not keen for surgical resection * eligible for endoscopic intervention * written informed consent exclusion criteria: * coagulopathy (international normalized ratio \>1.3, partial thromboplastin time greater than twice that of control), platelet count \<50,000x103/ul * pregnancy * patients with a poor mental condition or mental retardation, unable to understand the nature and possible consequences of the study * patients unwilling to undergo follow-up assessments * patients with liver cirrhosis, portal hypertension and/or gastric varices.

Keywords: eus-guided rfa liver stomach adrenal kidney tumour
dose-dependent effect of early antiplatelet therapy in acute ischemic stroke

Conditions: Test the Efficacy of Antiplatelet Regimes in Acute Stroke

Summary: the aim of this study is to evaluate the low-response prevalence of early antiplatelet therapy and to test the influence of different aspirin dosages in patients with acute ischemic strokes (ais).

antiplatelet agents are important therapeutic options in treating patients with acute ischemic strokes to prevent recurrent ischemic events or death. the aim of this study was to evaluate the low-response prevalence of early antiplatelet therapy and the influence of different aspirin dosages in patients with acute ischemic strokes (ais).

Eligibility criteria:
inclusion criteria: * suspected acute cerebrovascular ischemic events and patients who were admitted to the stroke unit where antiplatelet therapy was initiated exclusion criteria: * severe liver disorders, current gastrointestinal disorders, congestive heart failure, life-threatening malignancies and a personal or family history of bleeding disorders

Keywords: aspirin, acute cerebrovascular ischemia, platelet function
effect of ramosetron on post-discharge nausea and vomiting

Conditions: Hysteroscopy

Summary: nausea and vomiting after general anesthesia is one of the common anesthetic complications. if the patient is discharged from the hospital after surgery, proper treatment may be delayed or impossible if nausea or vomiting occurs. thus, it is necessary to prevent these symptoms beforehand. patients who underwent gynecologic surgery will be treated with prophylactic ramosetron to determine whether the frequency of nausea and vomiting is decreased when the patient returned home after discharge.


Eligibility criteria:
inclusion criteria: * patients who undergo hysteroscopic surgery and are discharged on the day of surgery. exclusion criteria: * american society of anesthesiologists physical statue 3 or more * planned admission after surgery * intravenous anesthesia * during chemotherapy * pregnancy or breastfeeding * abnormal liver or kidney function
plaque registration and event detection in computed tomography

Conditions: Atherosclerosis; Cardiovascular Diseases; Coronary Artery Disease

Summary: disruption of an atherosclerotic plaque is responsible for at least two-thirds of acute coronary syndrome. thus, identification of plaques vulnerable to rupture has become important. the natural history of individual plaques is unknown and needs to be established. multidetector computed tomography (mdct) angiography is a useful noninvasive imaging modality for assessing coronary plaque characteristics. using mdct, the researchers prospectively investigate the relationship between the characterization of coronary plaques and cardiovascular events in a large multicenter study.


Eligibility criteria:
inclusion criteria: * patients with known or suspected coronary artery disease. exclusion criteria: * irregular heart beat, * known allergy towards the contrast agent, * renal dysfunction, * uncontrolled heart failure, * previous coronary bypass surgery, or pacemaker or icd implantation, st elevation mi or unstable hemodynamic condition, * impossible breath-hold, or * end-stage cancer.